Abstract
In the last decade there has been significant progress in the new treatment options for NSCLC (non small cell lung cancer). However, resistence arises in all therapeutic modalities (chemotherapy, targeted / biological therapy, immunotherapy) for advanced lung cancer after certain time.
This issue is widely debated in the context of targeted therapy - e.g. epidermal grow factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Our article shows a case report of a patient with changing EGFR status.
There was a change notified between a primary resected tumor and tumor recurrence. In addition, remarkable efficacy of EGFR-TKI (erlotinib) in the presence of EGFR mutation T790M is documented.
These findings have been briefly discussed with published literal facts. In this context, the future of our patient should focus on efficacy of 3rd generation of EGFR- TKIs and the ability to monitor the development of cancer genome by using so called liquid biopsy.